



## Newsletter

### Evidence based guideline Guillain-Barre Syndrome

A multidisciplinary evidence based guideline on diagnostics and treatment of Guillain-Barre Syndrome was developed by a collaboration of the Vereniging Spierziekten Nederland (VSN), Nederlandse Vereniging voor Neurologie (NVN) and Nederlandse Vereniging van Revalidatieartsen (VRA). The guideline is available through the [website](#) of the CBO.

### New therapeutic indication for KIOVIG: MMN

On June 23rd 2011 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN). With adoption by the European Commission, Baxter will receive marketing authorization for KIOVIG MMN indication in all European Union (EU) Member States- the first centrally-licensed indication for an immunoglobulin preparation for MMN.

### Angel award for Maryze Schoneveld

Maryze Schoneveld van der Linde received during the Rare disease day in Amsterdam the Angel Award. This award is for a person who has made special efforts for people with rare diseases. Maryze has Pompe's disease and has been active for more than 15 years for the International Pompe Association (IPA) and VSCA (respiratory care). Nationally and internationally she is recognised for her many efforts in supporting patients with rare diseases.

### Evidence-based guideline: Treatment of painful diabetic neuropathy

The American Academy of Neurology has published a new guideline for the treatment of painful diabetic neuropathy (PDN). Results suggest that pregabalin is established as effective and should be offered for relief of PDN (Level A). Venlafaxine, duloxetine, amitriptyline, gabapentin, valproate, opioids (morphine sulfate, tramadol, and oxycodone controlled-release), and capsaicin are probably effective and should be considered for treatment of PDN (Level B). [Read more](#)

### Agenda

#### August

31 European Conference on Post Polio Syndrome

#### September

10 European Federation of Neurological Sciences Congress (EFNS)

25 American Neurological Association Meeting (ANA)

28 Meeting Belgian Dutch neuromuscular studyclub

#### October

11 International congress of Human Genetics

18 World Muscle Society Congress (WMS)

#### November

08 Treat-NMD International Conference

### Deadline Prinses Beatrix Fonds Year award 2011

Deadline for submission of a paper for the Prinses Beatrix Fonds Year award is October 17<sup>th</sup> 2011. For more information on submission of a paper: [Read more](#).



### Jan 13th 2012: ISNO symposium neuromuscular disorders

On Friday January 13th 2012, the yearly ISNO neuromuscular disorders meeting will take place in Amsterdam. The program will soon be available on the [ISNO website](#).

### New trials

[click here for all trials](#)

Disorder	Treatment	Centre	Start date
DMD	Phase III - efficacy and safety of GSK2402968 (PRO051)	LUMC	01/05/2011
ALS	Phase III - Dexamipexol	UMCU	01/06/2011